2020
Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy
Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. Blood 2020, 136: 11-12. DOI: 10.1182/blood-2020-139752.Peer-Reviewed Original ResearchEvent-free survivalDuration of responseMRD-negative CRIntensive chemotherapyOverall survivalDay 1Complete remissionFree survivalHematologic improvementOlder patientsSecondary AMLPD-1Study armsAML patientsInitial treatmentHematologic disordersLeukemia-specific T-cell responsesCancer Therapy Evaluation ProgramCR/complete remissionImmune cell subsets analysisRandomized phase 2 studyRandomized phase 2 trialRandomized phase II studyAllogeneic stem cell transplantBetter long-term clinical outcomes
1998
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998, 82: 1506-1512. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineFemaleHeartHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLungLymphoma, Non-HodgkinMaleMelphalanMiddle AgedNeutropeniaNeutrophilsPodophyllotoxinRespiratory Function TestsRetrospective StudiesVentricular Function, LeftConceptsHigh-dose chemotherapyPulmonary function testsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationProgenitor cell transplantationPBPC transplantationDose chemotherapyVital capacityCell transplantationAutologous peripheral blood progenitor cell transplantationAbnormal pulmonary function testsVentricular ejection fraction valuesHigh-dose therapyTotal lung capacityTime of reevaluationEjection fraction valuesEquilibrium radionuclide angiographyMediastinal irradiationAdditional therapyComplete remissionDose therapyPulmonary symptomsExpiratory volumePulmonary functionPFT values